Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 27 for “"PARP inhibitor"”.
-
Parp Inhibitor Upregulates Pd-L1 Expression and Enhances Cancer-Associated Immunosuppression
… patient response to cytotoxic anticancer agents. Inhibitors of poly (ADP-ribose) polymerase (PARP) have shown substantial cytotoxic effects against tumors with defects in DNA damage responses. However, whether a crosstalk between PARP inhibition and immune checkpoints exists remains unclear. Here, …
-
Receptor Tyrosine Kinases-Mediated Acquired Parp Inhibitor Resistance In Breast Cancer
… Small molecule poly(ADP-ribose) polymerase (PARP) inhibitors (PARP-is) have been approved for clinical use in treating breast cancer and ovarian cancer patients bearing DDR-deficient tumors with mutations in breast cancer susceptibility genes (<em>BRCA</em><sup>m</sup>). However, accumulating …
-
Role of C-Met and Egfr In Acquired Resistance to Parp Inhibitors In Triple-Negative Breast Cancer
… are limited. The Poly (ADP-ribose) polymerase (PARP) inhibitors, olaparib and talazoparib, were recently approved for metastatic breast cancer (including triple-negative breast cancer) in patients with a germline <em>BRCA1/2</em> mutation. Despite impressive response rates of ~60%, the …
-
In-depth bioinformatics analysis of the phosphoproteome of triple negative breast cancer treated with a tumor selective NQO1 bioactivatable drug
… in killing breast cancer cells compared to PARP inhibitor Rucaparib. From this proteomics study, large changes in phosphorylation are observed in utilizing a combination therapy with low dose of IB-DNQ and PARP inhibitor Rucaparib. Protein phosphorylation events within the transcription …
-
Tracking Treatment Response and Resistance to Parp Inhibition (Talazoparib) In Hereditary Pancreatic Cancer.
<p>polyADP ribose polymerase (PARP) inhibitors are a class of drugs that block the PARP enzymes, involved in the repair of singe-stranded DNA breaks through the base excision repair pathway. PARP inhibition leads to replication-associated double stranded DNA breaks, which are repaired by homologous …
-
Targeting DNA Repair in Prostate Cancer: Therapeutic Combinations & Disease Models
Targeting prostate cancer cells with DNA repair inhibitors presents an opportunity to improve outcomes in patients with poor prognosis cancers. There are multiple reasons which rationalise targeting DNA repair in prostate cancer, including the enrichment of DNA repair genetic alterations in men …
-
The impact of chronic loss of STAG2 on DNA damage repair and the epigenome in acute myeloid leukaemia
… in ΔSTAG2 cells and excitingly, this conferred PARP inhibitor sensitivity. To further investigate the potential for therapeutic targeting of ΔSTAG2 the isogenic cells were screened against Selleckchem’s DNA Damaging Compounds Library identifying 32 compounds to which mutant cells were …
-
Monosacchacharid-Konjugate von Inhibitoren der O6-Methylguanin-DNA Methyltransferase, der Poly-(ADP-ribose) Polymerase und des SWITCH Phänomens des HIV Hüllproteins gp120 : Synthese, biologische Aktivität und Struktur-Wirkungsbeziehungen
… sind. So wurden O6-substituierten Purine zu MGMT-Inhibitor-Glucosiden, eine Hydroxyphenyl-benzimidazol-Grundstruktur zu PARP-Inhibitor-Glucosiden und Isochinolindion-Grundstrukturen zu SWITCH-Inhibitor-Glucosiden umgesetzt. Gegenüber dem 'Goldstandard' der MGMT-Inhibitoren, dem O6-Benzylguanin …
-
Investigating the role of protein ubiquitylation in the maintenance of genome stability
… lethality with the poly-ADP ribose polymerase (PARP) inhibitor olaparib, as a means of screening for new HR factors. In this manner, I identify the E2 ubiquitin conjugating enzyme UBE2S as a novel factor required for olaparib resistance, and confirm its direct involvement in DNA repair by …
-
Shedding Light on the Biological Effects of Ionising Radiation on DNA Using Advanced Optical Microscopy
… compared to low-LET gamma-rays. Additionally, PARP inhibitor Olaparib in combination with IR resulted in increased foci persistence. Although Ku70/Ku80 are known as major effectors in DSB repair and genome integrity, their interaction in relation to DSB repair has not been detected in living …
-
Unravelling the Spatial and Temporal Heterogeneity of High-Grade Serous Ovarian Cancer Using Imaging-Based Biomarkers
… treatment clinical trial to predict and compare PARP inhibitor and immunotherapy responses over time. Chapter 6 presents an interpretable radiomics framework as a feasibility study to predict changes in tumour composition under neoadjuvant chemotherapy (NACT) from pre-treatment baseline scans. …
-
Micro and nanotechnology for cancer treatment
… into whole blood. Specifically, we modify a PARP inhibitor (Olabarib) and conjugate it to a dextran coated iron oxide nanoparticle. We measure the presence of the drug nanosensor based on the change in T2 relaxation time using a miniaturized, handheld NMR sensor for point-of-care diagnosis. …
-
Clinical Significance of Homologous Recombination Deficiency Score Testing In Endometrial Cancer
… mice injected with Hec1a and treated with PARP inhibitor had significantly decreased tumor growth and HR function as compared with untreated controls, regardless of BRCA1 function.</p> <p><strong>Conclusions: </strong>High HRD score was associated with worse survival in our patient cohort. …
-
Poly (Adp) Ribose Polymerase Inhibitors For The Treatment of Malignant Peripheral Nerve Sheath Tumor
… MPNST patients. Poly (ADP) ribose polymerase (PARP) inhibitors were first reported over a decade ago to have substantial anti-tumorigenic effects in malignancies with defective DNA repair, specifically those with <em>BRCA1/2</em> (breast cancer, early onset 1/2)<em> </em>mutations. Further …
-
Pharmacological activation of pro-survival pathways as a strategy for improving donor heart preservation
… the cardioprotective effects of a novel inhibitor of poly(ADP-ribose) polymerase 1, INO-1153. Maximum protective effect (after a 6 hour storage period) was observed when the PARP inhibitor was administered prior to cardiac arrest and storage and when the agent was added to the Celsior …
-
Identifying and Targeting Adaptive Changes to Bet Inhibition In Ovarian Cancer
… Bromodomain and Extra-Terminal Domain (BET) inhibitors in a mechanism driven fashion to maximize anti-tumor activity, and to determine the efficacy of BET inhibitor combinations in pre-clinical ovarian cancer mouse models.</p> <p><strong>Experimental Design: </strong>We used a novel, …
-
53BP1 and double-strand break repair pathway choice in cancer
… phenomenon has relevance for the development of PARP (Poly(ADP-ribose) polymerase) inhibitor resistance, now being used in BRCA1-deficient breast, ovarian and prostate cancers based on the principle of ‘synthetic lethality’. As part of a search for other resistance mechanisms, we identified the …
-
EVALUATION OF THE RISK OF SECONDARY LEUKEMIAS IN CANCER SURVIVORS
… clinical settings: 73 lymphomas patients and 58 PARP-inhibitor (PARPi)-eligible ovarian cancer (EOC) patients after platinum-based chemotherapy. We used high-sensitivity error-corrected sequencing (limit of sensitivity VAF>0.1%) for CH analysis, in order to detect mutations well below the cutoff …
-
Deciphering The Role of miR-506 in Ovarian Cancer Drug Sensitivity
… ATM signalling pathway, sensitising EOC cells to PARP inhibitor olaparib. Acting in the same way, miR-506 expression was synthetic lethal with Chk1 and Wee1 checkpoint kinases inhibitors in agreement with recent data reporting RAD17 depletion to be synthetically lethal with these small molecules. …
Page 1 of 2